Updates

21 September 2026 To To National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, 25th floor, P. J. Towers, Bandra (E), Mumbai – 400 051 Dalal Street, Mumbai – 400 001 Scrip Symbol: COHANCE Scrip Code – 543064 Dear Sir/Madam, Sub: Intimation regarding completion of USFDA Inspection at Company’s API manufacturing facility at Jaggaiahpet, Andhra Pradesh We wish to inform you that the United States Food and Drug Administration (USFDA) inspected the Company’s API manufacturing facility at Jaggaiahpet, Andhra Pradesh, India (FEI No. 3005554260), from 14 September to 19 September 2026. The inspection concluded with the issuance of a Form FDA 483 containing five observations. The Company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline. The Company remains committed to quality and regulatory compliance. Kindly take the above information on record. Thank you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K Mishra Company Secretary and Compliance Officer